Overview of Glp 1 Receptor Agonists Impact On Cardio Renal Outcomes

Here, the authors show that GLP-1 RAs are associated with reduced mortality and improved cardio-renal outcomes in type 2 diabetes patients with acute kidney disease.

This discrepancy underscores the complexity of translating clinical trial results into broader patient populations and suggests that the impact of short-acting GLP-1 RAs on kidney outcomes may ...
Cardiovascular and Renal Outcomes of GLP

Abstract Background: Glucagon-like peptide-1 receptor agonists ( GLP -1RAs) have emerged as a foundational therapeutic option for type 2 diabetes mellitus (T2DM), offering glycemic control and cardiovascular benefits. This systematic review and meta-analysis evaluates the impact of GLP -1RAs on cardiovascular outcomes in patients with T2DM.
Background The effect of glucagon-like peptide-1 ( GLP-1 ) receptor agonists -based therapies on cardiovascular and renal outcomes has not been systematically reviewed across baseline kidney function groups. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) with GLP-1 Receptor Agonists (RAs) in patients with and without chronic kidney disease (CKD). Methods ...

effect of GLP
Glucagon-like peptide-1 receptor agonists ( GLP -1RAs) have established cardiovascular benefits and glycaemic control effects in patients with type 2 diabetes. Evidence regarding the effect of GLP -1RAs on renal outcomes has been inconsistent across individual clinical trials.
Glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) are widely used in patients with chronic kidney disease (CKD), but existing evidence regarding their efficacy and safety remains inconsistent. To evaluate the cardiorenal outcomes and adverse effects of GLP-1 RAs in this population, we conducted …

Updated evidence on cardiovascular and renal effects of GLP
Glucagon-like peptide-1 receptor agonists ( GLP -1RAs) have a reliable hypoglycaemic and weight-loss effect that can intervene in obesity, which is the basis of type 2 diabetes pathology. GLP -1RA therapy has shown potential benefits in reducing the risk of major adverse cardiovascular events and improving kidney outcomes in patients with diabetes at high risk for cardiovascular disease. More ...
However, whether GLP-1 receptor agonists improve clinically important kidney outcomes remains uncertain. We aimed to comprehensively assess the effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes by performing a meta-analysis of randomised controlled trials.

Key Details About Glp 1 Receptor Agonists Impact On Cardio Renal Outcomes
Glucagon-like peptide-1 ( GLP-1 ) receptor agonists are incretin-based therapies initially developed for the management of type 2 diabetes. In addition to improving glycemic control and promoting weight loss, these agents have demonstrated cardiovascular and potential renal benefits. This review explores the mechanisms by which GLP-1 receptor agonists may exert renoprotective effects, including ...






Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials